Lilly’s Q2 2026 Playbook: Momentum, Manufacturing, and the M&A Engine That Won’t Quit

Executive snapshot

• Ticker: LLY
• Q2 revenue: $23.0 billion, up about 48% year over year
• Q2 EPS: GAAP $7.94; non-GAAP $8.38
• IPR&D charges: $3.03 in Q2
• 2026 revenue forecast: raised to the $85.0–$87.0 billion range
• EPS guidance: $35.50–$36.50 at the midpoint
• Key products: Mounjaro and Zepbound remain the growth engines
• Regulatory/regulatory progress: FDA approval for Ebglyss (maintenance dose every eight weeks) and EC approval of Jaypirca as monotherapy; orforglipron submission in the U.S.
• Capital allocation: ~$4.5 billion committed to Indiana manufacturing; active M&A program with multiple deals and post-quarter activity

What drove the numbers

Lilly’s Q2 momentum is anchored in the weight-loss/diabetes axis—the duo of retatrutide-driven demand paired with continued performance from Mounjaro and Zepbound. Revenue surged 48% to $23.0 billion, a figure largely powered by volume. The company also cataloged one-time IPR&D charges of $3.03 billion, a reminder that big growth engines carry accounting quirks that complicate the earnings line.

On the guidance side, Lilly has pushed the revenue forecast higher and reiterated a robust EPS target, suggesting management believes the topline rebound is self-funding to an extent and that the pipeline will continue to contribute in the back half. The combined signal: more revenue, a more ambitious profit target, and a strategy thick with pipeline options and manufacturing leverage.

The Q2 release also underscores a broader strategic bet: scale manufacturing to unlock demand, while financing growth through acquisitions and development, not just drugs cleared by a single approval vote. It’s a plan that reads less like a one-quarter lift and more like a multi-year playbook.

Strategic moves and capital allocation

Beyond the quarterly numbers, Lilly’s press release maps a diversified growth trajectory. The company has disclosed the acquisitions of Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Kelonia Therapeutics, with three additional acquisitions completed after the quarter. The goal: build an infectious disease and broader biotech portfolio alongside its GLP-1 franchise. The timing of these deals dovetails with a capital plan that includes a substantial Indiana manufacturing expansion—about $4.5 billion—to support current products and future launches.

These moves aren’t just about more assets on the shelf; they are about turning pipeline strength into real-world capacity and scale. The Indianapolis address in the filing isn’t just a mailing label; it’s a signal of a company leaning into domestic production and supply resilience in a world where demand for these therapies is both global and persistent.

Market implications for Lilly and peers

The quarter is a reminder that the most valuable pharmaceutical franchises increasingly depend on a three-part engine: clinical data that moves the stock price, regulatory milestones that unlock new revenue streams, and the manufacturing backbone that makes it real. A stronger revenue forecast paired with a higher EPS target can lift sentiment for Lilly and could nudge sector peers higher on expectations for pipeline acceleration and capex efforts.

For sector peers, Lilly’s results may amplify a few trends: the potency of GLP-1–class assets and obesity solutions, the strategic importance of multi-quarter data packages, and the discipline of deploying capital toward capacity alongside acquisitions. The market will be watching not just the headline numbers, but whether the earnings power can outpace the IPR&D charges and whether the efficiency of the manufacturing expansion materializes in improved margins.

Risks and questions to watch

• How durable is the revenue growth if new entrants compete in obesity/weight-loss markets, and how will pricing dynamics evolve?
• What is the margin trajectory as Lilly absorbs manufacturing expansion and integrates acquisitions?
• How will ongoing regulatory developments shape the pipeline, and will orforglipron or other candidates reach the U.S. market on schedule?
• What does the trajectory of EPS look like relative to the EPS consensus and how does the company navigate potential earnings surprises?
• Is the current guidance a sustainable runway or a near-term lift that depends on continued high-volume sales of GLP-1 therapies?

Conclusion: a growth engine with a busy workshop

Lilly’s Q2 2026 results sketch a company that can deliver a strong top line while retooling its growth engine for the long haul. The EPS numbers sit alongside a higher revenue forecast and a capital plan that leans into manufacturing scale and aggressive M&A. If the pipeline data keep delivering and regulatory progress remains favorable, the company could convert this period of rapid growth into structural earnings power. For investors, the ticker LLY remains a lens into how a legacy pharma company can blend blockbuster products with an assertive, capital-intensive expansion strategy.